Clinical Trials Browser

Uterine Cervical Neoplasms

NCT06266338 2026-05-06

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

Phase 2 Recruiting

30 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT07223424 2026-04-16

PSI-Immune

Phase 2 Recruiting

880 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma Of Esophagus, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Colitis, Ulcerative, Colonic Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

132 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05082259 2026-02-10

ASTEROID

Phase 1 Recruiting

61 enrolled

BreastGynecologic

Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms

NCT07368985 2026-01-27

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

Phase 2 Not yet recruiting

87 enrolled

Gynecologic

Adenocarcinoma, Uterine Cervical Neoplasms

NCT06640283 2025-12-24

ANA

Phase 2 Recruiting

150 enrolled

GastrointestinalGynecologic

Anal Canal Carcinoma, Uterine Cervical Neoplasms

NCT04157985 2025-12-11

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Phase 3 Completed

161 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT04865887 2025-10-07

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Phase 2 Recruiting

35 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT02635360 2025-07-03

Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

Phase 2 Completed

94 enrolled 16 charts

Gynecologic

Uterine Cervical Neoplasms

NCT04483544 2025-04-29

Pembrolizumab and Olaparib in Cervical Cancer Patients

Phase 2 Terminated

8 enrolled 13 charts

Gynecologic

Uterine Cervical Neoplasms

NCT04357873 2025-02-19

PEVOsq

Phase 2 Completed

112 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Penile Neoplasms, Vulvar Neoplasms, Neoplasms, Squamous Cell

NCT06805864 2025-02-03

BROTHER

Phase 2 Not yet recruiting

45 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT03755739 2024-06-25

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Phase 2/3 Recruiting

200 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Uterine Cervical Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT03367871 2024-06-18

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

Phase 2 Terminated

17 enrolled 12 charts

Gynecologic

Uterine Cervical Neoplasms

NCT04187872 2023-12-27

TORCH

Phase 1 Terminated

10 enrolled

CNSDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT04641728 2022-08-09

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Phase 2 Unknown

28 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Phase 2 Terminated

5 enrolled

Gynecologic

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT03192059 2021-09-08

PRIMMO

Phase 2 Completed

43 enrolled

Gynecologic

Uterine Cervical Neoplasms, Uterine Neoplasms, Endometrial Neoplasms

Clinical Trials

PAPAYA

Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)

PSI-Immune

PNeoVCA

ASTEROID

Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer

ANA

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Pembrolizumab and Lenvatinib in Advanced Cervical Cancer

Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

Pembrolizumab and Olaparib in Cervical Cancer Patients

PEVOsq

BROTHER

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer

TORCH

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

PRIMMO